Lv6
2410 积分 2022-06-16 加入
娃娃鱼
EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Upregulation of CD47
7个月前
已关闭
First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer
7个月前
已完结
Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer
9个月前
已完结
Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM)
10个月前
已完结
The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment
1年前
已完结
Adjuvant Treatments for Surgically Resected Non–Small Cell Lung Cancer Harboring EGFR Mutations
1年前
已完结
Can Radiomics Bridge the Gap Between Immunotherapy and Precision Medicine in Lung Cancer?
1年前
已完结
Editorial Commentary: Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC
1年前
已完结
IL-6 mediates suppression of T and NK cells function in EMT-associated TKI-resistant EGFR mutant NSCLC<
1年前
已完结
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
1年前
已完结
皖公网安备34019202002308
